Get started
Author

Jeremy Aboagye

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
2020 · Merryn Voysey, Sue Ann Costa Clemens, et al. · The Lancet · 4,692
PDF
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
2020 · Pedro M Folegatti, Katie J Ewer, et al. · The Lancet · 2,414
PDF
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
2021 · Merryn Voysey, Sue Ann Costa Clemens, et al. · The Lancet · 1,128
PDF
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2020 · Katie J. Ewer, Jordan R. Barrett, et al. · Nature Medicine · 585
PDF
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
2020 · Jordan R. Barrett, Sandra Belij-Rammerstorfer, et al. · Nature Medicine · 309
PDF
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
2022 · Mehreen S Datoo, Hamtandi Magloire Natama, et al. · The Lancet Infectious Diseases · 296
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
2021 · Amy Flaxman, Natalie G Marchevsky, et al. · The Lancet · 247
PDF
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
2022 · Meera Madhavan, Adam J. Ritchie, et al. · EBioMedicine · 139
PDF
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
2024 · Nora Schmit, Hillary M Topazian, et al. · The Lancet Infectious Diseases · 56
PDF
Safety and Immunogenicity of the ChadOx1 nCoV-19 (AZD1222) Vaccine in Children Aged 12-17 Years: A Preliminary Report of a Phase 2, Single-Blind, Randomised Controlled Trial (COV006)
2021 · Grace Li, Federica Cappuccini, et al. · The Lancet · 42
PDF
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
2022 · Daniel Jenkin, Adam J Ritchie, et al. · The Lancet Microbe · 34
PDF
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya
2023 · Samuel Sang, Mehreen S. Datoo, et al. · Wellcome Open Research · 15
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
2023 · Merryn Voysey, Amy Flaxman, et al. · Clinical & Experimental Immunology · 14
PDF
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
2021 · Jordan R. Barrett, Sandra Belij-Rammerstorfer, et al. · Nature Medicine · 13
PDF
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2021 · Katie J. Ewer, Jordan R. Barrett, et al. · Nature Medicine · 7
PDF
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
2021 · Pedro M. Folegatti, Amy Flaxman, et al. · Vaccines · 6
PDF
A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease
2025 · Jeremy Sanderson, Jeremy Aboagye, et al. · EBioMedicine · 4
Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
2023 · Sang, Samuel, Datoo, Mehreen, et al. · Harvard Dataverse · 1
Cationic surfactant-dependent enhancement of antigen-specific cellular immunity by a biodegradable nanoparticle vaccine
2026 · Jorge Huete-Carrasco, Jeremy Aboagye, et al. · Vaccine
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)
2025 · Grace Li, Natalie G. Marchevsky, et al. · Vaccine
Works count: 20
Citation count: 10,000
H-index: 13
I10-index: 14
Year
Topic
Type